NEW ENGLAND BIOLABS

Company Overview

New England Biolabs (NEB), founded in 1974, develops and markets tools and reagents for analysis and purification of DNA, RNA and proteins. In the NGS market, NEB supplies target enrichment and library preparation products.

In the field of NGS-based liquid biopsy, New England Biolab’s target enrichment and library construction products can be used on the back end of the liquid biopsy workflow. The objective is to reduce the time for converting a genomic DNA sample into sequence-ready libraries to about six hours.

NEB’s NGS sample preparation products include NEBNext Ultra Directional RNA, NEBNext Ultra DNA, and NEBNext Fast DNA Fragmentation & Library Prep.

The NEBNext DNA Repair Mix can be used together with NEB’s library preparation reagents to provide a complete workflow for preparation of DNA from FFPE samples. This workflow can be used with either Illumina or Ion Torrent sequencing instruments.

NEBNext Direct for target enrichment (enables sensitive variant calling) and NEBNext Direct Cancer HotSpot Panel (hybridization-based capture of 190 common cancer targets from 50 genes) were introduced in 2016.

For CTC analysis, NEB markets PicoPlex single-cell WGA kits that are manufactured by Rubicon Genomics.

The single-cell, whole genome amplification techniques include multiple displacement amplification (MDA), multiple annealing and looping-based amplification cycles (MALBAC), or PicoPlex single-cell WGA methods.

Amplification methods can be compared on the following parameters: DNA gain from amplification and sequence features achieved (coverage uniformity, error rate, and ease of producing genome assemblies or of discovering genetic variants).

In May 2021, New England Biolabs (NEB) acquired Fluorogenics Ltd. (FGL), facilitating the integration of NEB’s enzymology expertise with FGL’s extensive knowledge of the lyophilization process. This synergy will enable NEB to offer a comprehensive solution to its customers and strengthens its capability to serve clients in the molecular diagnostics sector.